LONDON There is alarm, concern and even heartbreak across the biotech and pharma industry and among leading scientists at the vote to leave the EU.
"This is not the outcome the Bioindustry Association wanted," Steve Bates, CEO told BioWorld Today.
"Key questions about the regulation of medicine, access to the single market and talent, intellectual property and the precise nature of the future relationship of the U.K. with Europe, are now upon us," Bates said.
He was echoed by Mike Thompson, CEO of the Association of the British Pharmaceutical Industry, who said, "This creates immediate challenges for future investment, research and jobs in our industry in the U.K."
Similarly, member of parliament Nicola Blackwood, chair of the house of commons science and technology committee, said, "It is vital that the government moves quickly to reassure our scientists and their collaborators in Europe that the U.K.